GlycoMark (1,5-AG): What This Test Actually Measures

What Is 1,5-Anhydroglucitol?

1,5-anhydroglucitol is a naturally occurring polyol found in nearly all foods, especially grains, seafood, and dairy. The body maintains a large, stable pool of 1,5-AG in the blood because daily intake roughly matches daily excretion. Under normal glycemic conditions, the kidneys reabsorb almost all filtered 1,5-AG back into the bloodstream 1.

How 1,5-AG Relates to Glucose

The renal tubule transporter that reabsorbs 1,5-AG also reabsorbs glucose, and glucose wins the competition. When blood glucose exceeds approximately 180 mg/dL (the renal threshold), glucose floods the tubules, blocks 1,5-AG reabsorption, and 1,5-AG spills into the urine. The circulating 1,5-AG level falls. Each hyperglycemic episode pulls the level down further, and recovery takes about two weeks of stable normoglycemia.

Why This Matters Clinically

This mechanism makes 1,5-AG a real-time scorecard for glucose spikes. HbA1c averages all glucose exposure over 2 to 3 months, smoothing out peaks and valleys. Two patients with identical A1c values of 7.0% can have dramatically different spike patterns, and 1,5-AG reveals that difference 2.

How the GlycoMark Test Works

The GlycoMark assay is the only FDA-cleared test for measuring serum 1,5-AG in the United States. It uses an enzymatic colorimetric method to quantify 1,5-AG concentrations from a standard blood draw.

Sample Collection

No fasting is required. The test uses a routine serum or plasma sample, drawn by venipuncture. Results are reported in micrograms per milliliter (mcg/mL).

The Inverse Relationship

GlycoMark results move in the opposite direction from most diabetes biomarkers. A higher 1,5-AG level means better glucose control. A lower value means worse control, specifically more frequent or more severe postprandial spikes. This inverse logic trips up clinicians unfamiliar with the test, so it bears repeating: low is bad, high is good.

Timeframe of Measurement

Because the body's 1,5-AG pool replenishes slowly after a glucose spike, the test reflects glycemic events from the past 1 to 2 weeks. This positions it between a point-in-time fasting glucose reading and the 2 to 3 month lookback of HbA1c 3.

Normal GlycoMark (1,5-AG) Ranges

Reference ranges differ slightly by sex, age, and the laboratory running the assay. The values below reflect the GlycoMark FDA-cleared reference intervals.

| Population | Normal Range | |---|---| | Males | 10.7 to 32.0 mcg/mL | | Females | 6.8 to 29.3 mcg/mL | | Combined clinical cutoff | ≥10.0 mcg/mL generally suggests infrequent spikes |

Interpreting Values Above 10 mcg/mL

Values above 10 mcg/mL in a patient with diabetes suggest that blood glucose is rarely exceeding the renal threshold. These patients may still have elevated HbA1c from chronic moderate hyperglycemia, but their postprandial peaks are contained.

Interpreting Values Below 10 mcg/mL

A 1,5-AG level below 10 mcg/mL indicates that glucose is regularly breaching 180 mg/dL. Values below 5 mcg/mL suggest severe and frequent postprandial hyperglycemia 4. A 2012 study published in Diabetes Care (N=206) found that 1,5-AG values <5 mcg/mL correlated with postprandial glucose excursions exceeding 200 mg/dL on continuous glucose monitoring.

1,5-AG vs. HbA1c vs. Fructosamine

Each glycemic biomarker answers a different clinical question. Using them together builds a more complete picture.

HbA1c: The 2 to 3 Month Average

HbA1c reflects average blood glucose over the lifespan of red blood cells (approximately 90 to 120 days). The American Diabetes Association (ADA) recommends an A1c target of <7.0% for most adults with diabetes 5. A1c does not distinguish between steady glucose of 155 mg/dL all day and wild swings from 80 to 280 mg/dL that average to the same number.

Fructosamine: The 2 to 3 Week Average

Fructosamine measures glycated serum proteins and reflects average glucose over 2 to 3 weeks. It is useful when A1c is unreliable (hemoglobin variants, hemolytic anemia, recent transfusion) but still captures averages, not peaks.

Where 1,5-AG Fills the Gap

1,5-AG is the only standard lab biomarker that specifically targets postprandial hyperglycemia. A 2009 study in Diabetes Technology & Therapeutics (N=103) demonstrated that 1,5-AG correlated more strongly with postprandial glucose area under the curve (r = -0.65) than HbA1c did (r = -0.43) 6.

HealthRX Glycemic Biomarker Decision Framework:

• A1c only ≥7%: Start with A1c-guided therapy adjustments.
• A1c at goal but symptoms persist (fatigue after meals, reactive hypoglycemia patterns): Order 1,5-AG to detect hidden spikes.
• A1c unreliable (hemoglobinopathy, CKD, recent transfusion): Use fructosamine for average control, add 1,5-AG for spike detection.
• A1c at goal and 1,5-AG <10 mcg/mL: Postprandial spikes need targeted intervention (mealtime insulin adjustment, GLP-1 agonist addition, or carbohydrate strategy changes).

When Clinicians Order GlycoMark

Ordering 1,5-AG is most useful in specific clinical scenarios where standard markers leave unanswered questions.

Patients with "Good" A1c but Poor Outcomes

Some patients maintain A1c values of 6.5% to 7.5% yet develop microvascular complications at rates higher than expected. A 2008 analysis from the ARIC (Atherosclerosis Risk in Communities) study (N=11,106) found that low 1,5-AG independently predicted cardiovascular events even after adjusting for A1c 7. This suggests that the spike pattern, not just the average, contributes to vascular damage.

Gestational Diabetes Monitoring

Postprandial glucose control is the primary target in gestational diabetes management. The American College of Obstetricians and Gynecologists (ACOG) recommends 1-hour postprandial targets of <140 mg/dL 8. 1,5-AG can serve as an objective between-visit check on whether a patient is meeting those postprandial targets, especially when self-monitored blood glucose logs are incomplete.

Medication Adjustment Decisions

Because 1,5-AG reflects a 1 to 2 week window, it responds faster than A1c to treatment changes. Clinicians titrating mealtime insulin, adding a GLP-1 receptor agonist, or modifying carbohydrate intake can see the impact on postprandial spikes within two weeks rather than waiting three months for A1c to shift.

What Makes 1,5-AG Go Low (and How to Raise It)

A falling 1,5-AG is a direct consequence of glucose exceeding the renal threshold. The interventions that raise 1,5-AG are the same ones that reduce postprandial spikes.

Dietary Modifications

Reducing high-glycemic carbohydrate loads at meals is the most direct lever. Pairing carbohydrates with protein and fat slows gastric emptying and blunts glucose peaks. A randomized crossover trial (N=16) published in Diabetes Care found that eating vegetables and protein before carbohydrates reduced postprandial glucose by 29% compared to the reverse order 9.

Medication Strategies

GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) reduce postprandial glucose through slowed gastric emptying and glucose-dependent insulin secretion. In the SUSTAIN-1 trial (N=388), semaglutide 1.0 mg reduced postprandial glucose increments by approximately 3.6 mmol/L compared to placebo 10. Rapid-acting mealtime insulin analogs (lispro, aspart) also target postprandial peaks directly.

Exercise Timing

A post-meal walk of 15 to 30 minutes can lower postprandial glucose by 20 to 40 mg/dL. A 2016 meta-analysis in Sports Medicine (N=612 across 15 studies) confirmed that post-meal exercise reduces postprandial glycemia significantly more than pre-meal or no exercise 11.

Limitations and Interfering Factors

The GlycoMark test has specific clinical scenarios where results become unreliable or uninterpretable.

SGLT2 Inhibitor Use

Sodium-glucose cotransporter 2 (SGLT2) inhibitors (empagliflozin, dapagliflozin, canagliflozin) lower the renal threshold for glucose reabsorption by design. This mechanism also blocks 1,5-AG reabsorption regardless of glucose levels, producing falsely low 1,5-AG readings. The AACE 2023 guidelines note that 1,5-AG should not be used in patients taking SGLT2 inhibitors 12.

Chronic Kidney Disease

Patients with an eGFR below approximately 45 mL/min/1.73m² have impaired renal handling of 1,5-AG. Results in this population do not reliably reflect glycemic status and should be interpreted with caution.

Severe Hyperglycemia (A1c >10%)

When A1c exceeds roughly 10%, 1,5-AG values are often so depleted (frequently <2 mcg/mL) that the test loses its ability to discriminate between degrees of poor control. The test is most informative in the A1c range of 6.5% to 9.0%, where it adds the most unique information about spike burden 13.

Other Interfering Conditions

Liver cirrhosis, gastrectomy, and acarbose use can all alter 1,5-AG levels independent of glucose control. Pregnancy itself lowers 1,5-AG due to increased plasma volume and altered renal physiology, so gestational diabetes interpretation requires pregnancy-specific reference ranges.

How to Interpret Results with Your Provider

Understanding a GlycoMark result requires context. The number alone is insufficient.

Step 1: Confirm No Interfering Medications or Conditions

Rule out SGLT2 inhibitor use, advanced CKD, and liver disease before interpreting the result.

Step 2: Compare Against Your A1c

The most actionable clinical finding is a discordance: A1c at or near goal but 1,5-AG below 10 mcg/mL. This combination signals hidden postprandial hyperglycemia that A1c is masking.

"When we see a disconnect between a well-controlled A1c and a low 1,5-AG, it tells us the patient is spending significant time above 180 mg/dL after meals, and that spike exposure carries independent cardiovascular risk," states the Endocrine Society's 2022 clinical practice advisory on glycemic monitoring 14.

Step 3: Correlate with CGM Data if Available

For patients using continuous glucose monitors, 1,5-AG and time-above-range (TAR, percent of readings >180 mg/dL) should track together. A 2019 study in Journal of Diabetes Science and Technology (N=79) found a strong inverse correlation (r = -0.71) between 1,5-AG and CGM-derived TAR 15. If CGM is not available, 1,5-AG provides an objective proxy for spike frequency.

Insurance Coverage and Cost

GlycoMark is covered by most major insurance plans when ordered with a diagnosis code for diabetes mellitus (Type 1 or Type 2) or gestational diabetes.

Typical Out-of-Pocket Cost

Without insurance, the test costs approximately $30 to $75 at most reference laboratories. With insurance, copays are typically the same as any routine blood test.

CPT Code

The relevant CPT code is 84378 (1,5-anhydroglucitol). Some labs may bill under a general chemistry panel code if bundled with other glucose markers.

Emerging Research on 1,5-AG

Interest in 1,5-AG extends beyond diabetes management.

Cardiovascular Risk Prediction

The ARIC study follow-up data (N=11,106, median follow-up 20 years) showed that low 1,5-AG predicted incident heart failure, coronary heart disease, and ischemic stroke independent of A1c and fasting glucose 7. Postprandial glucose spikes trigger endothelial dysfunction, oxidative stress, and inflammation through mechanisms distinct from chronic steady-state hyperglycemia.

Pregnancy Outcomes

A 2020 prospective cohort study in Diabetes Care (N=2,802) found that low 1,5-AG in early pregnancy predicted large-for-gestational-age births even among women who did not meet diagnostic criteria for gestational diabetes on oral glucose tolerance testing 16. This raises the question of whether postprandial glucose variability in pregnancy matters even below conventional diagnostic thresholds.

"1,5-AG may help us identify a subset of pregnant women with subclinical postprandial dysglycemia who are currently missed by standard screening," noted the study's lead author, Michael Y. Tsai, PhD, Department of Laboratory Medicine and Pathology, University of Minnesota.

Integration with Digital Health

As continuous glucose monitors become more common, some endocrinologists use 1,5-AG as a validation check. A quarterly 1,5-AG can confirm that CGM-derived metrics (time in range, TAR) are tracking accurately and that sensor drift is not producing falsely reassuring readings.

The Bottom Line on GlycoMark

1,5-AG is the only standard blood test that specifically detects postprandial glucose spikes over the past 1 to 2 weeks. For patients with A1c values between 6.5% and 9.0% who are not taking SGLT2 inhibitors, a 1,5-AG level below 10.0 mcg/mL should prompt a focused evaluation of mealtime glucose patterns, dietary timing, and possible addition of spike-targeting therapies such as GLP-1 receptor agonists or rapid-acting mealtime insulin.